Tokushi Tachiwada
Kagoshima University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tokushi Tachiwada.
European Journal of Cancer | 2012
Kazumori Kawakami; Hideki Enokida; Takeshi Chiyomaru; Shuichi Tatarano; Hirofumi Yoshino; Ichiro Kagara; Takenari Gotanda; Tokushi Tachiwada; Kenryu Nishiyama; Nijiro Nohata; Naohiko Seki; Masayuki Nakagawa
PURPOSE The aim of this study was to find a novel molecular network involved in renal cell carcinoma (RCC) development through investigating the functions of miR-1 and miR-133a and their target genes. METHODS We checked the expression levels of miR-1 and miR-133a in RCC cell lines and specimens (N=40) using real time RT-PCR. MiR-1 and miR-133a transfectants were subjected to a gain-of-function study to identify the functions of the miRNAs. To find the target genes of the miRNAs, we analysed the gene expression profile of their transfectants and performed a luciferase reporter assay. mRNA expression levels of the candidate target gene in the clinical specimens were examined, and loss-of-function studies were performed. RESULTS The expression levels of miR-1 and miR-133a were significantly suppressed in RCC cell lines and specimens. Ectopic restoration of miR-1 and miR-133a showed significant inhibition of cell proliferation and invasion, and moreover, revealed induction of apoptosis and cell cycle arrest. The luciferase assay revealed transgelin-2 (TAGLN2), selected as a target gene for miR-1 and miR-133a on the basis of the gene expression profile, to be directly regulated by both miR-1 and miR-133a. The loss-of-function studies showed significant inhibitions of cell proliferation and invasion in the si-TAGLN2 transfectant. The expression level of TAGLN2 mRNA was significantly up-regulated in the RCC specimens; in addition, there was a statistically significant inverse correlation between TAGLN2 and miR-1 and miR-133a expression. CONCLUSIONS Our data indicate that up-regulation of the oncogenic TAGLN2 was due to down-regulation of tumour-suppressive miR-1 and miR-133a in human RCC.
Molecular and Cellular Biology | 2002
Misako Haraguchi; Hiroaki Tsujimoto; Masakazu Fukushima; Itsuro Higuchi; Hideto Kuribayashi; Hideo Utsumi; Atsuo Nakayama; Yoshio Hashizume; Junko Hirato; Hiroki Yoshida; Hiromitsu Hara; Shinjiro Hamano; Hiroaki Kawaguchi; Tatsuhiko Furukawa; Kohei Miyazono; Fuyuki Ishikawa; Hideo Toyoshima; Tadashi Kaname; Masaharu Komatsu; Zhe-Sheng Chen; Takenari Gotanda; Tokushi Tachiwada; Tomoyuki Sumizawa; Kazutaka Miyadera; Mitsuhiro Osame; Tetsuo Noda; Yuji Yamada; Shin-ichi Akiyama
ABSTRACT Thymidine phosphorylase (TP) regulates intracellular and plasma thymidine levels. TP deficiency is hypothesized to (i) increase levels of thymidine in plasma, (ii) lead to mitochondrial DNA alterations, and (iii) cause mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). In order to elucidate the physiological roles of TP, we generated mice deficient in the TP gene. Although TP activity in the liver was inhibited in these mice, it was fully maintained in the small intestine. Murine uridine phosphorylase (UP), unlike human UP, cleaves thymidine, as well as uridine. We therefore generated TP-UP double-knockout (TP−/− UP−/−) mice. TP activities were inhibited in TP−/− UP−/− mice, and the level of thymidine in the plasma of TP−/− UP−/− mice was higher than for TP−/− mice. Unexpectedly, we could not observe alterations of mitochondrial DNA or pathological changes in the muscles of the TP−/− UP−/− mice, even when these mice were fed thymidine for 7 months. However, we did find hyperintense lesions on magnetic resonance T2 maps in the brain and axonal edema by electron microscopic study of the brain in TP−/− UP−/− mice. These findings suggested that the inhibition of TP activity caused the elevation of pyrimidine levels in plasma and consequent axonal swelling in the brains of mice. Since lesions in the brain do not appear to be due to mitochondrial alterations and pathological changes in the muscle were not found, this model will provide further insights into the causes of MNGIE.
International Journal of Oncology | 2012
Shuichi Tatarano; Takeshi Chiyomaru; Kazumori Kawakami; Hideki Enokida; Hirofumi Yoshino; Hideo Hidaka; Nijiro Nohata; Takeshi Yamasaki; Takenari Gotanda; Tokushi Tachiwada; Naohiko Seki; Masayuki Nakagawa
Our previous studies suggested that microRNA (miR)-574-3p is a candidate tumor suppressor microRNA (miRNA) in human bladder cancer (BC). Among 17 down-regulated miRNAs, miR-574-3p is located on chromosome 4p14 where we had identified a chromosomal loss region by array-CGH in BC cell lines. MiR-574-3p expression was down-regulated in BC cell lines. Gain-of-function analysis revealed that cell proliferation, migration and invasion were significantly inhibited in miR-574-3p-transfected BC cell lines. Flow cytometry analysis showed that cell apoptosis was induced in miR-574-3p transfectants. Oligo microarray analysis suggested that the mesoderm development candidate 1 (MESDC1) gene was a target gene in miR-574-3p transfectants. Luciferase assays revealed that miR-574-3p was directly bound to MESDC1 mRNA. MESDC1 is predicted to be a novel actin-binding protein located on chromosome 15q13. Although the gene is conserved among many species, its functional role is still unknown in both human malignancies and normal tissues. Loss-of-function studies demonstrated that cell proliferation, migration and invasion were significantly inhibited in si-MESDC1-transfected BC cell lines. Flow cytometry analysis showed that apoptosis was induced in si-MESDC1 transfectants. We are the first to demonstrate that miR-574-3p is a miRNA with tumor suppressor function and that MESDC1 (which has a potential oncogenic function in BC) may be targeted by miR-574-3p.
Biochemistry | 2007
Jill K. Paterson; Suneet Shukla; Chelsea M. Black; Tokushi Tachiwada; Susan Garfield; Stephen Wincovitch; David Ernst; Anissa Agadir; Xuelin Li; Suresh V. Ambudkar; Gergely Szakács; Shin-ichi Akiyama; Michael M. Gottesman
Oncology Reports | 2006
Kazumori Kawakami; Hideki Enokida; Tokushi Tachiwada; Takenari Gotanda; Kengo Tsuneyoshi; Hiroyuki Kubo; Kenryu Nishiyama; Masaki Takiguchi; Masayuki Nakagawa; Naohiko Seki
Biochemical and Biophysical Research Communications | 2012
Hirofumi Yoshino; Hideki Enokida; Takeshi Chiyomaru; Shuichi Tatarano; Hideo Hidaka; Takeshi Yamasaki; Takenari Gotannda; Tokushi Tachiwada; Nijiro Nohata; Takashi Yamane; Naohiko Seki; Masayuki Nakagawa
The Journal of Urology | 2007
Kazumori Kawakami; Hideki Enokida; Tokushi Tachiwada; Kenryu Nishiyama; Naohiko Seki; Masayuki Nakagawa
International Journal of Molecular Medicine | 2006
Takenari Gotanda; Misako Haraguchi; Tokushi Tachiwada; Reiko Shinkura; Chihaya Koriyama; Suminori Akiba; Motoshi Kawahara; Kenryu Nishiyama; Tomoyuki Sumizawa; Tatsuhiko Furukawa; Hiromitsu Mimata; Yoshio Nomura; Shin-ichi Akiyama; Masayuki Nakagawa
Oncology Reports | 2007
Tokushi Tachiwada; Zhe-Sheng Chen; Xiao-Fang Che; Mitsugu Matsumoto; Misako Haraguchi; Takenari Gotanda; Tomoyuki Sumizawa; Tatsuhiko Furukawa; Kenryu Nishiyama; Naohiko Seki; Masatatsu Yamamoto; Masayuki Nakagawa; Shin-ichi Akiyama
Cancer Letters | 2006
Kengo Tsuneyoshi; Misako Haraguchi; Zhao Hongye; Takenari Gotanda; Tokushi Tachiwada; Tomoyuki Sumizawa; Tatsuhiko Furukawa; Masanori Baba; Shin-ichi Akiyama; Masayuki Nakagawa